Skip to main content
. 2021 May 5;41(18):4131–4140. doi: 10.1523/JNEUROSCI.2521-20.2021

Figure 3.

Figure 3.

The antidepressant effects of intra-LHb injection of (R)-ketamine or (S)-ketamine in CRS rats. A, Schematic illustration of experimental protocol of (R)-ketamine. B, The verified infusion sites. C, Effect of intra-LHb injection of (R)-ketamine on the LMA. n.s., Not significant. n = 6–10. D, Effect of intra-LHb injection of (R,S)-ketamine on the immobile time in the FST. n.s., Not significant. n = 6–9. E, Effect of intra-LHb injection of (R)-ketamine on the latency to immobility onset of FST. n.s., Not significant. n = 6 and 7. F, Effect of intra-LHb injection of (R)-ketamine on the SPT. n.s., Not significant. n = 6–8. Five rats were removed from the analysis for incorrect cannulae placement (C–F). G, Schematic illustration of experimental protocol of (S)-ketamine. H, The verified infusion sites. I, Effect of intra-LHb injection of (S)-ketamine on the LMA. n.s., Not significant. n = 6–10. J, Effect of intra-LHb injection of (S)-ketamine on the immobile time in the FST. ***p < 0.001, n.s., not significant. n = 6–8. K, Effect of intra-LHb injection of (S)-ketamine on the latency to immobility onset of FST. **p < 0.01, n.s., not significant. n = 6–9. L, Effect of intra-LHb injection of (S)-ketamine on SPT. *p < 0.05, n.s., not significant. n = 6–9. Four rats were removed from the analysis for incorrect cannulae placement (I–L). LMA, Locomotion activity.